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Background: Studies have revealed both higher cancer survival in the US than in Germany and substantial
improvement of cancer survival in the past in these countries. This population-based study aims at comparing most
recent 5-year relative survival of breast cancer patients and preceding trends in both countries.
Methods: Women with a first invasive breast cancer diagnosed and followed up between 1988 and 2008 from
Germany and the US (utilizing data from the Saarland Cancer Registry and the Surveillance, Epidemiology, and End
Results Program, respectively) were included. Period analysis was used to derive most up-to-date 5-year relative
survival and preceding survival trends according to age and stage.
Results: Since 1993, age standardized relative survival has steadily improved in Germany and the US to 83% and
88%, respectively. In the period 2005–08, relative survival of localized cancer was above 97% in both countries, and
79% and 83% for locally/regionally spread breast cancer, respectively. Prognosis of metastasized disease has
remained very poor overall, with improvement essentially being restricted to younger patients. The proportion of
patients diagnosed with localized breast cancer was consistently higher in the US. If adjusted for stage, the
differences in relative survival between both countries diminished over time and eventually disappeared.
Conclusions: Similar survival is now observed in both countries for patients below the age of 70 years, but in
Germany survival is still much lower for elderly patients. The observed trends point to treatment advances as a
major cause for improved survival. However, substantial differences in mammography usage existed between both
countries and might probably also account for the observed differences (to a lesser extent, also differences in
health care systems, and delivery of cancer care). Encouraging, survival of breast cancer patients has improved in
Germany to a much greater extent than in the US, albeit the persisting survival gap for elderly patients in Germany
requires particular attention by researchers, public health authorities, and clinicians.
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Population-based studies have shown a decrease in breast
cancer (BRC) mortality during the past two decades in
Germany and the US [1-3] primarily attributed to early
detection activities and advances in cancer treatment
[4,5] and demonstrated ongoing and substantial improve-
ment of long-term survival of BRC patients [6-8]. Studies
have also revealed higher BRC survival in the US than in
Germany and other European countries [9-12].
Prolongation of cancer survival may have two principal
causes: firstly anticipation of tumour diagnosis or even
overdiagnosis by early detection and secondly increased
survival due to improved effectiveness of cancer treat-
ment. The time gained if a cancer is diagnosed earlier in
a pre symptomatic stage due to screening is called lead
time and artificially increases survival time. By itself,
early detection does not affect the course of the disease.
Therefore, screening requires treatment administered
earlier to be effective and to postpone the death of the
patient.
Overdiagnosis results from detection of malignant
lesions that would never have progressed and presented
clinically during the patient’s lifetime and survival ana-
lyses yield too optimistic estimates due to the inclusion
of these non fatal cancers.
Therefore, comparative studies of population-based
cancer survival should particularly take into account dif-
ferences in stage distribution and early detection activ-
ities, to understand underlying mechanisms of observed
trends over time or differences between populations.
Up to now, available comparative population-based
studies on BRC survival were often limited as they pro-
vided survival trends stratified by age only (e.g. [6,7,9])
or reported stage-stratified survival only for singular cal-
endar years [10,11].
A recently published study reported trends of BRC
survival by age and stage in Germany [13]. This paper
aims at comparing most recent 5-year survival of female
BRC patients and preceding trends in Germany and the
US by age and stage and discussing the results in the
context of observed trends of BRC incidence and mor-
tality, and available data on the implementation and
usage of mammography screening and advances in BRC
treatment in these countries in the past.
Methods
Database
For Germany, data from the population-based Saarland
Cancer Registry were used. The registry covers the federal
state of Saarland, Germany, with approximately 1.04 mil-
lion residents in 2006 and operates since the beginning of
the 1970s. Cancer notification is mandatory by law. The
registry obtains notifications from pathology laboratories,
hospitals, radiotherapy departments, outpatient clinics,and general practitioners. The completeness of case ascer-
tainment is estimated above 95% [14,15].
The database from Saarland included 16,014 women
aged 15 years or older diagnosed with invasive BRC
(ICD-10 code: C50) between 1988 and 2008 (irrespective
of previous primary cancers of other sites). Patients with
a previous primary malignant tumour of the breast were
excluded.
Mortality follow-up based on death certificates was
available until end of 2008. Linkage with population
registries was additionally performed for all patients
assumed alive end of 2008 to identify patients lost to
follow-up. Patients having migrated out of the Saarland
region contributed survival time until removal. Patients
for whom linkage with population registries was not
possible (e.g. due to erroneous patient identifiers) were
classified as "no follow-up available" and excluded from
the analyses.
For the US, data from the Surveillance, Epidemiology,
and End Results Program (SEER) were used and
included the SEER-9 registries (states of Connecticut,
Iowa, New Mexico, Utah, Hawaii, metropolitan regions
of San Francisco-Oakland, Detroit, Atlanta, and Seattle
Puget Sound area) from 1988 with extension to the
SEER-13 registries (Alaska, regions of San Jose-
Monterey, Los Angeles and Rural Georgia) from 1992
until 2008, covering a population of approximately 41.2
million residents in 2004–08 [16]. The survival analyses
included 460,049 BRC patients based on criteria as
above. Mortality follow-up was available until end of
2008.
The following data items were used: month and year
of diagnosis, age at diagnosis, T classification, stage
(categories: ‘localized’: T1-3N0M0 tumours; ‘local/re-
gional spread’: T4M0 and N+M0 tumours; ‘distant me-
tastasis’: any M1 tumours; unknown extent), basis of
diagnosis, month and year of end of follow-up and vital
status. Stage was classified according to summary stage
reported by the registries or TNM information [17-19].
Clinical extent was used if no pathologic stage was avail-
able. For age-specific analyses, three age categories were
used: 15–49, 50–69, and 70+ years. Patients with
tumours notified from a death certificate only (DCO)
were excluded from survival analyses, as were patients
for whom no follow-up was available (Saarland only).
Additionally, incidence data of invasive and in situ
BRC (ICD-10 codes: C50 and D05), mortality data (ICD-
10 codes: C50), and population data were used from the
registries.
The data used for this study are routinely collected by
cancer registries according to state legislation for the
purpose of monitoring cancer incidence, mortality, and
outcomes and the anonymized data were used according
to the respective provisions for the use of research data.
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Age-standardized rates (ASR) and truncated age-
standardized rates (TASR) per 100,000 person years using
the 2000 US standard population [20] were calculated for
BRC incidence and mortality for successive calendar peri-
ods of four years between 1989 and 2008 in Germany and
the US (all races combined). To account for differences in
the registration of multiple primaries, for incidence esti-
mation of invasive and in situ BRC, only the first cancer
of the respective tumour type was considered.
A description of the BRC patients with regard to age,
T classification, stage, basis of diagnosis, and DCO noti-
fication was provided for intervals of four calendar years
between 1989 and 2008.
Relative survival (RS) which quantifies excess mortality
due to the cancer (capturing both direct and indirect
mortality) was derived as ratio of observed survival and
expected survival for these persons derived from life
tables of the underlying populations with respect to sex,
age and calendar time (race was also considered for US
patients) [21]. The Ederer II method was used to derive
expected survival [22].
Life tables for Saarland were calculated for intervals of
5 years since 1990 from mortality and population data
for single ages provided by the state statistical office (fur-
ther details may be found elsewhere [13]). Region- and
race-specific life tables for the US were derived from
mortality and population data included the SEER data-
base [23,24] for intervals of five calendar years since
1993 using the Elandt-Johnson method [25,26]. Race-
specific life tables were either provided for white, black,
and other races (three regions), white and races other
than white (eight regions), and all races combined (two
regions), according to the populations and numbers of
deaths [27].
Period analysis was used to obtain most up-to-date
estimates of RS. In addition to right censoring, observa-
tions are left truncated at the beginning of a calendar
period [28]. Extensive empirical evaluation has shown
that period estimates closely predict survival observed
for the patients diagnosed in the respective calendar
period [28-31]. In case of ongoing improvement, period
analysis provides survival predictions as up-to-date as
possible.
Period estimates of 5-year RS were derived for subse-
quent calendar periods of four years between 1993 and
2008. To avoid potential artefacts when combining clas-
sical cohort based estimates derived for calendar periods
with complete follow-up and period estimates for the
most recent calendar period, the period approach was
continuously used for the entire study period.
To test for linear trend in RS over time, model based
period analysis was employed. Poisson regression models
for relative survival were fitted modelling the logarithmof the excess number of deaths with a linear predictor of
follow-up year (categorical), age group (categorical) and
calendar period (numerical), incorporating the logarithm
of person time as offset [32]. A significance level of 0.05
(based on a two sided Wald test) was applied.
Besides crude survival, age standardized survival was
derived as weighted average of age group-specific sur-
vival based on weights from the International Cancer
Survival Standards (ICSS) [33]. Throughout the text, age
standardized estimates are presented as overall survival.
For both countries, stage information and T classifica-
tion were reasonably complete (>70%) after 1988. Stage
mix-adjusted survival was calculated using the stage dis-
tribution of the US patients diagnosed between 1988
and 2008. Standard errors were based on Greenwoods
method [34]. The R Language and Environment for Stat-
istical Computing (release 2.11.1; R Foundation for Stat-
istical Computing, Vienna, 2011) and the add-on
package ‘periodR’ (release 1.0-5) [35] were used for data
preparation and analysis.
Results
Table 1 shows trends of BRC incidence and mortality in
Germany and the US. At the beginning of the 1990s, age
standardized incidence of invasive BRC was higher in
the US than in Germany but converged due to a decrease
in the US among women aged 70+ years and an increase
in Germany among women aged 50+ years to 113 and
111 new cases per 100,000, respectively, in 2005–08.
Median age at diagnosis was lower in the US than in
Germany (60 and 65 years, respectively).
Age standardized incidence of in situ BRC was about
four-fold in the US compared to Germany (ASR: 30.3 vs.
8.5, respectively, in 2005–08). In the US, incidence
among women aged 50+ years was similar and 5-fold
compared to younger patients (TASR increased to 79.7
and 76.6 vs. 16.7, respectively, in 2005–08). In Germany,
the incidence approximately tripled among patients aged
50–69 years (TASR: 22.6) and doubled among the other
age groups (TASR: 5.8 and 14.9, respectively).
During the study period, a decrease of BRC mortality
was observed in the US across all age categories (ASR:
minus 28% to 23.1 in 2005–08), whereas in Germany
mortality slightly decreased only among patients below
70 years of age but increased among older ones (ASR
remained virtually unchanged: -3% to 30.4).
Table 2 presents characteristics of the included
patients. The number of women diagnosed during each
calendar period of four years has continuously increased.
Most recently, the proportion of patients below 70 years
of age was somewhat higher in the US than in Germany
(71.5% vs. 65.6%, respectively). From 1989 through 2008,
summary stage was available for 97.2% of the patients
from the US, and for 81.6% of the German patients. The
Table 1 Breast cancer incidence and mortality in Germany and the US
Germany (Saarland) US (SEER 9/13 regions) b
1989-92 1993-96 1997-00 2001-04 2005-08 1989-92 1993-96 1997-00 2001-04 2005-08
incidence of invasive BRC crude rate 115.7 128.8 140.7 153.2 162.9 118.2 115.8 124.3 120.0 118.7
ASR a 91.5 99.8 106.5 108.9 111.6 123.5 122.1 127.6 119.1 113.2
15-49 (TASR a) 56.1 56.2 59.1 53.5 57.5 60.7 57.1 58.1 57.2 57.7
50-69 (TASR a) 194.9 230.2 259.7 278.6 286.6 286.0 295.1 316.0 294.0 275.5
70+ (TASR a) 293.1 311.9 310.2 329.2 320.6 433.5 419.4 431.6 388.3 358.9
incidence of in situ BRC crude rate 4.3 5.8 8.3 10.8 11.4 17.2 19.6 27.2 29.4 31.6
ASR a 3.8 4.9 6.7 8.4 8.5 18.6 21.1 28.3 29.4 30.3
15-49 (TASR a) 3.2 4.0 4.3 6.0 5.8 11.4 11.3 14.6 15.1 16.7
50-69 (TASR a) 7.9 11.9 19.8 23.4 22.6 47.9 57.0 77.2 80.7 79.7
70+ (TASR a) 7.7 7.7 9.6 11.7 14.9 42.7 52.5 72.1 74.3 76.6
BRC mortality crude rate 44.1 47.4 50.3 48.2 49.3 30.0 28.6 26.0 24.9 24.7
ASR a 33.4 34.2 34.7 31.9 30.4 31.9 29.7 26.2 24.2 23.1
15-49 (TASR a) 13.2 12.5 11.7 8.8 7.1 11.0 9.7 8.3 7.4 7.0
50-69 (TASR a) 73.0 75.2 74.9 73.0 66.1 72.2 65.9 57.5 52.3 48.8
70+ (TASR a) 143.7 152.2 162.0 152.2 159.0 141.3 137.1 124.0 117.8 114.2
Incidence of invasive and in situ BRC (ICD-10 codes: C50/D05) and BRC mortality (ICD-10 code: C50) of women in Germany (Saarland) and the US (SEER 9/13
regions) between 1989 and 2008.
BRC: breast cancer; ASR: age standardized rate; TASR: truncated age standardized rate; rates given as new cases/deaths per 100,000; for incidence, only the first
tumour of the respective type was considered; a the US2000 standard population was used for standardization; b the coverage of SEER program was extended
from 9 to 13 registries in 1992.
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disease was continuously lower in Saarland than in the
US (44.8% and 49.7% vs. 60.6% and 63.1%, respectively,
in 2005–08). Almost all diagnoses were based on micro-
scopic examinations (97.2% and 99.0%, respectively, in
2005–08). In the study period, the overall proportions of
DCO notified BRC were 2.5% in Germany and 0.6% in
the US, respectively.
Trends of 5-year RS between 1993 and 2008 stratified
by age group and stage are given in Table 3. Since 1993,
overall age-standardized 5-year RS has steadily improved
in both countries. Survival was much higher in the US
than in Germany. However, the increase in 5-year RS
was stronger in Germany (+10.3% units to 82.5% vs.
+3.9% units to 88.1% in the US, respectively; p-values:
<0.001), and the pre existing gap between both coun-
tries has diminished.
In Germany, survival of patients aged 70+ years did not
improve to the same extent as survival of younger
patients (+5.6% units to 74.9% vs. +13.5% units to 88.4%
in 2005–08; p-values: 0.026 and <0.001, respectively). In
the US, survival of elderly patients improved to a lesser
extent (+2.1% units to 85.7% vs. +5.3% to 89.7%; p-values:
0.001 and <0.001, respectively). As a result, a difference of
about 11% units persisted in 5-year RS of elderly patients
between Germany and the US.
Age standardized 5-year RS of localized BRC was
98.7% in Germany and 97.3% in the US in 2005–08.Five-year RS of BRC with local or regional spread was
78.6% and 82.8%, respectively. If distant sites were
already involved at diagnosis time, 5-year RS was 23.7%
and 26.7% in both countries, respectively.
Since 1993, most improvement of age standardized
5-year RS was observed in Germany for locally/regionally
spread BRC, followed by localized disease (+14.6% units
and +7.3% units, respectively; p-values: <0.001). At the
same time, improvement of survival of US patients who
already had much better prognosis in 1993–96, was less
pronounced (+7.6% units and +1.6% units, respectively;
p-values: <0.001) and the gap in 5-year RS between both
countries reduced to 4.2% units and 1.4% units in 2005–
08, respectively. Survival of distant BRC improved by
3.3% units (p-value: 0.106) in Germany and by 6.5% units
in the US (p-value: <0.001).
Part of the overall survival differences between Ger-
many and the US resulted from a higher proportion of
patients with less advanced BRC in the US. Adjustment
for stage mix reduced survival differences between both
countries. In 2005–08, these differences eventually had
disappeared (87.9% and 88.1%, respectively).
Differences in most recent stage-specific 5-year RS
and preceding trends between patients aged>= 70 years
and younger ones were varying. Survival of patients with
localized BRC was equally high among elderly and
younger patients (in 2005–08, it was 96.6% vs. 97.8%
and 97.4% vs. 97.2%, respectively, in Germany and the
Table 2 Characteristics of included breast cancer patients
Category 1989-1992 1993-1996 1997-2000 2001-2004 2005-2008
n % n % n % n % n %
Germany (Saarland)
overall 2,564 2,877 3,118 3,354 3,494
age 15-49 years 514 20.0 537 18.7 637 20.4 594 17.7 640 18.3
50-69 years 1,179 46.0 1,322 46.0 1,418 45.5 1,591 47.4 1,653 47.3
>= 70 years 871 34.0 1,018 35.4 1,063 34.1 1,169 34.9 1,201 34.4
stage available 1,811 70.6 2,353 81.8 2,665 85.5 2,898 86.4 2,839 81.3
localized a 694 38.3 1,043 44.3 1,260 47.3 1,448 50.0 1,411 49.7
local/regional spread a 912 50.4 1,082 46.0 1,143 42.9 1,179 40.7 1,186 41.8
distant metastasis a 205 11.3 228 9.7 262 9.8 271 9.4 242 8.5
tumour size available 2,013 78.5 2,513 87.3 2,872 92.1 3,120 93.0 3,127 89.5
T1 a 661 32.8 921 36.6 1,126 39.2 1,384 44.4 1,402 44.8
T2 a 953 47.3 1,116 44.4 1,249 43.5 1,249 40.0 1,293 41.3
T3/4 a 399 19.8 476 18.9 497 17.3 487 15.6 432 13.8
microscopic confirmation 2,418 94.3 2,761 96.0 3,018 96.8 3,251 96.9 3,397 97.2
death certificate only notified 82 3.2 62 2.2 52 1.7 59 1.8 79 2.3
no follow-up available 64 2.5 43 1.5 79 2.5 67 2.0 49 1.4
US (SEER 9/13 regions b)
overall 64,556 87,228 97,713 97,579 98,857
age 15-49 years 15,314 23.7 21,103 24.2 23,124 23.7 23,592 24.2 23,731 24.0
50-69 years 27,007 41.8 36,641 42.0 42,501 43.5 44,147 45.2 46,914 47.5
>= 70 years 22,235 34.4 29,484 33.8 32,088 32.8 29,840 30.6 28,212 28.5
stage available 62,016 96.1 84,078 96.4 94,920 97.1 95,510 97.9 97,094 98.2
localized a 39,075 63.0 54,468 64.8 61,062 64.3 59,715 62.5 61,235 63.1
local/regional spread a 19,186 30.9 24,684 29.4 28,472 30.0 30,169 31.6 29,843 30.7
distant metastasis a 3,755 6.1 4,926 5.9 5,386 5.7 5,626 5.9 6,016 6.2
tumour size available 53,027 82.1 73,352 84.1 85,692 87.7 87,682 89.9 93,254 94.3
T1 a 33,518 63.2 47,364 64.6 55,847 65.2 56,038 63.9 56,522 60.6
T2 a 14,848 28.0 20,080 27.4 22,746 26.5 24,007 27.4 27,088 29.0
T3/4 a 4,661 8.8 5,908 8.1 7,099 8.3 7,637 8.7 9,644 10.3
microscopic confirmation 63,443 98.3 85,855 98.4 96,357 98.6 96,364 98.8 97,831 99.0
death certificate only notified 394 0.6 497 0.6 602 0.6 554 0.6 479 0.5
Characteristics of female breast cancer patients (ICD-10 code: C50) from Germany (Saarland) and the US (SEER 9/13 regions) diagnosed between 1989 and 2008.
a proportion among patients with available stage/T classification; b the coverage of SEER program was extended from 9 to 13 registries in 1992.
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BRC improved less and was much lower for elderly
patients in both countries (in 2005–08, it was 70.8% vs.
85.1% and 77.5% vs. 87.0%, respectively). Among
patients with metastasized BRC, improvements were
highest for patients <50 years of age (+18.2% units and
+11.9% units to 29.6% and 38.8%, respectively; p-values:
0.029 and <0.001), but no substantial improvement was
seen for elderly patients (changes of −1.8% units and
+2.1% units to 15.3% and 19.4%, respectively; p-values:
0.712 and 0.045).
Age standardized 5-year RS of BRC patients with un-
known or missing stage information was varying in both
countries. In Germany, it was about 80% during thestudy period. In the US, it varied slightly between 55%
and 58% between 1993 and 2004, but dropped to 45% in
the most recent calendar period.Discussion
In this study, most recent 5-year RS of female BRC
patients from Germany and the US and preceding trends
were analyzed using data from the population-based
Saarland Cancer Registry and the SEER 9/13 registries.
In 2005–08, age standardized 5-year RS was 82.5% and
88.1% for all stages combined, 98.7% and 97.3% for loca-
lized BRC, 78.6% and 82.8% for BRC with local or re-
gional spread and 23.7% and 26.7% for tumours with
Table 3 Five-year relative survival of breast cancer patients by age and stage
stage Germany (Saarland) US (SEER 9/13 regions a)
1993-96 1997-00 2001-04 2005-08 Δ p-value 1993-96 1997-00 2001-04 2005-08 Δ p-value
RS SE RS SE RS SE RS SE RS SE RS SE RS SE RS SE
overall crude 73.0 1.1 77.1 1.0 80.1 0.9 84.2 0.9 11.2 <0.001 84.1 0.2 86.3 0.2 88.2 0.1 88.6 0.1 4.5 <0.001
age std b 72.2 1.3 76.3 1.2 79.0 1.1 82.5 1.0 10.3 <0.001 84.2 0.2 86.3 0.2 88.2 0.2 88.1 0.2 3.9 <0.001
stage mix std c 78.8 1.1 82.3 0.9 85.3 0.8 87.9 0.7 9.1 <0.001 84.1 0.2 85.7 0.1 87.7 0.1 88.1 0.1 4.0 <0.001
15-49 years 75.4 2.0 78.6 1.8 83.9 1.6 87.7 1.4 12.3 <0.001 82.8 0.3 85.2 0.3 87.3 0.2 89.2 0.2 6.4 <0.001
50-69 years 74.7 1.4 79.1 1.3 81.7 1.1 88.6 1.0 14.0 <0.001 85.4 0.2 87.5 0.2 89.8 0.2 90.0 0.2 4.7 <0.001
15-69 years 74.9 1.2 78.9 1.0 82.3 0.9 88.4 0.8 13.5 <0.001 84.4 0.2 86.7 0.2 88.9 0.1 89.7 0.1 5.3 <0.001
>= 70 years 69.3 2.4 73.6 2.2 75.1 2.1 74.9 2.1 5.6 0.026 83.6 0.4 85.5 0.4 86.5 0.4 85.7 0.4 2.1 0.001
localized crude 90.7 1.5 93.3 1.2 96.0 1.0 97.5 0.9 6.8 0.002 95.4 0.2 96.1 0.2 97.0 0.2 97.2 0.1 1.8 <0.001
age std b 91.4 2.4 94.5 1.9 97.4 1.6 98.7 1.4 7.3 <0.001 95.7 0.2 96.3 0.2 97.3 0.2 97.3 0.2 1.6 <0.001
15-49 years 86.9 2.5 92.3 1.9 93.1 1.6 95.3 1.4 8.4 0.011 93.6 0.3 94.1 0.2 95.4 0.2 96.3 0.2 2.7 <0.001
50-69 years 91.7 1.8 91.6 1.5 95.4 1.2 98.7 0.9 7.0 0.001 95.4 0.2 96.4 0.2 97.4 0.2 97.6 0.2 2.2 <0.001
15-69 years 90.1 1.5 91.8 1.2 94.7 0.9 97.8 0.7 7.7 <0.001 94.8 0.2 95.6 0.1 96.8 0.1 97.2 0.1 2.4 <0.001
>= 70 years 93.2 4.6 98.3 3.5 99.9 2.9 96.6 2.9 3.4 0.555 96.7 0.5 97.0 0.4 97.5 0.4 97.4 0.4 0.7 0.290
T1 age std b 97.3 4.0 99.3 2.9 99.5 2.4 104.1 1.8 6.8 - 98.8 0.3 99.5 0.2 99.9 0.2 100.4 0.2 1.7 -
T2-3 age std b 89.4 3.7 92.1 2.9 93.9 2.4 92.1 2.4 2.7 0.110 86.3 0.6 87.0 0.5 89.7 0.5 89.3 0.5 3.0 <0.001
local/regional
spread
crude 65.2 1.8 70.9 1.7 76.4 1.5 81.1 1.5 15.9 <0.001 75.8 0.4 79.0 0.3 83.3 0.3 85.0 0.3 9.2 <0.001
age std b 64.0 2.2 70.3 2.0 74.8 1.9 78.6 1.8 14.6 <0.001 75.1 0.4 77.5 0.4 81.7 0.4 82.8 0.4 7.6 <0.001
15-49 years 70.7 3.4 71.4 3.1 81.1 2.7 82.6 2.6 11.9 0.004 75.5 0.6 80.2 0.5 83.5 0.4 86.8 0.4 11.3 <0.001
50-69 years 65.3 2.5 72.2 2.2 77.6 1.9 86.2 1.7 20.8 <0.001 78.1 0.5 80.6 0.4 86.3 0.3 87.1 0.3 9.1 <0.001
15-69 years 66.9 2.0 71.9 1.8 78.6 1.6 85.1 1.4 18.2 <0.001 76.9 0.4 80.4 0.3 85.2 0.3 87.0 0.2 10.0 <0.001
>= 70 years 61.1 4.0 68.7 3.7 70.5 3.7 70.8 3.6 9.7 0.084 72.4 0.9 74.3 0.8 76.7 0.8 77.5 0.8 5.1 <0.001
T1/2 age std b 73.0 3.1 79.3 2.7 84.4 2.4 85.6 2.2 12.6 <0.001 81.4 0.5 83.6 0.5 87.7 0.4 88.1 0.4 6.7 <0.001
T3/4 age std b 47.1 3.6 52.3 3.5 56.2 3.4 64.3 3.2 17.2 <0.001 64.3 1.0 68.1 0.9 71.7 0.8 68.8 0.8 4.5 0.001
distant
metastasis
crude 20.2 3.0 21.9 3.0 20.1 2.6 23.0 3.0 2.8 0.111 21.2 0.7 24.1 0.7 27.2 0.7 29.2 0.7 7.9 <0.001
age std b 20.3 3.2 22.1 3.0 19.0 2.6 23.7 3.0 3.3 0.106 20.2 0.7 22.5 0.7 25.2 0.7 26.7 0.7 6.5 <0.001
15-49 years 11.5 5.8 17.9 8.9 26.9 7.6 29.6 9.1 18.2 0.029 26.8 1.5 31.5 1.4 34.5 1.4 38.8 1.4 11.9 <0.001
50-69 years 25.3 4.4 24.7 4.4 23.6 4.0 29.1 4.6 3.8 0.237 21.3 1.0 24.4 1.0 29.0 1.0 30.5 1.0 9.2 <0.001
15-69 years 22.0 3.7 23.9 3.9 24.5 3.5 28.5 4.1 6.5 0.058 23.2 0.9 26.9 0.8 30.9 0.8 33.2 0.8 10.0 <0.001
>= 70 years 17.2 5.9 19.3 4.7 13.3 3.7 15.3 4.2 −1.9 0.712 17.4 1.1 18.2 1.1 19.0 1.1 19.4 1.1 2.1 0.045
unknown
stage
crude 78.4 2.5 81.3 2.8 77.0 3.5 81.4 2.8 3.0 0.381 55.2 1.2 57.7 1.2 55.0 1.4 43.5 1.5 −11.7 <0.001
age std b 78.7 2.5 82.1 2.7 77.6 3.2 82.7 2.5 4.0 0.084 55.6 1.3 59.0 1.2 56.1 1.5 45.2 1.6 −10.4 <0.001
Five-year relative survival of female patients with invasive breast cancer (ICD-10 code: C50) from Germany (Saarland) and the US (SEER 9/13 regions) by age and
stage for successive calendar periods.
RS: relative survival (period estimate) in %; SE: standard error; std: standardized; Δ : difference of RS between 2005–08 and 1993–96 in % units; a the coverage of
SEER program was extended from 9 to 13 registries in 1992; b using weights from the International Cancer Survival Standards [33]; c weights derived from the
SEER patients diagnosed 1988–2008.
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Germany and the US.
During the study period, most overall improvement of
5-year RS was observed for locally/regionally spread
BRC, followed by localized tumours. As increases were
more pronounced among German patients, the existing
discrepancies between the two countries have decreased
over time. Among patients with metastasized BRC, sub-
stantial improvement was seen only for patients below50 years of age. The differences in stage-adjusted sur-
vival have entirely disappeared over time.
In Germany, 5-year RS and its improvement over time
were inferior for patients aged 70+ years resulting both
in an increased age gradient in Germany and prevailing
differences in 5-year RS of elderly patients between the
two countries.
The health care systems differ fundamentally in both
countries. In Germany, health care is decentralized with
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providing most ambulatory and impatient care. In 2007,
95.7% of the population had health insurance coverage
through public or private health insurance [36]. In the
US, health care facilities largely belong to the private
sector and health insurance by private or government
health insurance schemes covered 84.7% of the popula-
tion in 2006/07 [37]. Both countries have a high stand-
ard of living and spend more than 10% of their gross
domestic product into health care [38].
In the US, organized breast cancer screening was
introduced (with regional differences and different types
of programs) at the beginning of the 1990s [39]. Wide-
spread use of mammography has been reported. The
proportion of women aged 50 years or older reporting to
have had a mammogram within the past two years
increased between 1987 and 2005 from 27.4% to 68.4%
[40,41].
In Germany, implementation of organized mammog-
raphy screening started only recently in 2003. The
quality-assured programme offers women aged 50 to
69 years a screening mammography every two years.
Prior to its introduction in 2006, only opportunistic
screening was available in Saarland [42]. In 2002–04,
45.3% of women aged 55 years or older residing in Saar-
land reported to have had a mammography within the
last two years (unpublished data from the population-
based ESTHER cohort study in Saarland [43,44]). For
2007–08, a proportion of 53% of eligible women partici-
pating in the organized screening was reported [45,46].
In the US, organized mammography screening started
earlier and was intensely used even among younger and
elderly women. Data on the usage of opportunistic
mammography from Germany prior to the introduction
of the organized screening are sparse. Based on the data
available, it may be assumed that mammography usage
and screening was much lower in Germany during the
study among all age categories.
Higher usage of mammography in the US compared
to Germany is well reflected in the presented incidence
data. Higher proportions of earlier stages and a fourfold
incidence of in situ tumours in the US correlate with the
differences in the adoption and intensity of mammog-
raphy screening [47-49].
Diagnosis of in situ lesions of the breast is usually
based on a microscopic examination and basis for a no-
tification from a pathology laboratory. According to the
registration practises of the SEER registries and the Saar-
land Cancer registry, we assumed the observed differ-
ences in incidence of in situ tumours to represent
differences in screening activities (or prevalence of risk
factors) rather than differences in case ascertainment.
The observed drop in incidence of invasive BRC in the
US after the year 2000 may reflect the change in theprescription of hormone replacement therapy [50,51],
whereas the implementation of mammography screening
probably interacts with this effect in Germany. However,
differences and changes in the prevalence of ‘traditional’
risk factors have also to be kept in mind. BRC mortality
started to decline at the end of the 1980s in the US and
approximately ten years later in Germany (data not
shown).
To account for overestimation of survival of patients
with screen detected cancers we performed analyses
stratified by age and stage. This at least partly allowed
combining patients with comparable stages with regard
to begin of follow up, even if lead time effects remain
present within all stages. Furthermore, beneficial effects
of screening have even been demonstrated between
clinically and screening detected tumours of same stage
[52].
The introduction of organized screening in Germany
at the end of the study period, the higher intensity of
mammography usage in the US on the one hand, and a
much higher increase in 5-year RS in Germany on the
other hand, support the presumption of advances in the
treatment of the disease and adoption of treatment
recommendations as a major cause of the remarkable
gain in survival in Germany and advanced disease during
the study period. However, increased early detection
surely has interfered with these developments. As an
observational study, it cannot fully resolve the contribu-
tions of improved treatment and screening as underlying
reasons of the striking increase of 5-year RS in
Germany.
Major advances in BRC treatment during the past
20 years included improved staging (e.g. more sensitive
medical imaging and sentinel node dissection), propaga-
tion of breast conserving surgery and adjuvant radio-
therapy for effective local treatment of early stage
disease and new agents for chemotherapy and antiestro-
gen treatment, and targeted biologic agents. Treatment
according to consensus recommendations and tailored
to the patient's individual risk and a wider range of treat-
ment options has increased the number of patients eli-
gible for cancer-specific treatments.
For elderly patients, co-morbidity and differences in the
delivery of cancer care are well documented (e.g. delay
in seeking cancer care and influences of co-morbidity
on selection of cancer treatments [53], lower likelihood
of receiving adjuvant radiotherapy or chemotherapy
compared to younger patients, even after adjustment for
co-morbidity and extent of disease [54-57]) and may ex-
plain inferior 5-year RS and its less pronounced increase
[58-60].
The widespread use of mammography among elderly
women in the US (the proportion of women aged 75+
years reporting to have had a mammogram within the
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1987 and 2005) [41] most likely exaggerated the increase
in survival over time among these patients and may have
partly concealed existing differences in age-specific sur-
vival in the US, as lead time effects and overdiagnosis
particularly strongly affect survival estimates of a popu-
lation segment with increased (age-related) mortality.
Nevertheless, the observed differences in the survival of
elderly patients between both countries – particularly
pronounced in locally/regionally advanced disease – may
point to possible limitations and hesitant delivery of care
to elderly patients in Germany.
In the interpretation of the findings, a number of lim-
itations and strengths should be considered. A major
limitation is the restricted availability of clinical informa-
tion. Although rather crude, the used staging scheme
allowed survival estimation for three rather distinct
groups of BRC patients with regard to available treat-
ment options. Tumour stage and T classification were
sufficiently complete.
The proportions of patients with missing stage were
much higher in Germany than in the US. Survival of
German patients with unknown stage was comparable to
overall survival. Survival of US patients with unknown
stage was much lower, possibly due to higher propor-
tions of patients with clinical cancers of more advanced
stage.
Further determinants beyond age and tumour stage,
e.g. information about administered treatments, socio-
economic status, or co-morbidity were not available.
Neither was the method of first detection to consider
screening effects as well as lead time, length time and
overdiagnosis [5,61].
The included registries operate as established registries
with high levels of completeness of case ascertainment
and follow-up [14-16,62]. So far, no other population-
based cancer registry from Germany may provide trend
data as presented in this article. Even if it constitutes
only 1.3% of the overall population, the Saarland region
is well representative for Germany and its health care
system and the size of its population allowed analyses
stratified by age and stage as most fundamental prognos-
tic factors with sufficient precision. However, when
interpreting point estimates of 5-year RS we also consid-
ered the corresponding trends, particularly for strata
with small numbers of subjects.
The 17 registries currently included in the SEER
programme cover approximately one fourth of the US
population. The covered regions are regarded reasonably
representative for the US, although the population is
categorized as somewhat more urban, with less un-
employment, higher education and higher smoking
prevalence [16,63,64]. One has to keep in mind, that
such population differences might also have affectedparticipation in mammography screening and access to
cancer care of the included SEER populations [65,66].
To avoid artefacts in the most recent survival trends
due to the inclusion of the four registries which joined
the SEER programme in 2000 (California regions,
Kentucky, Louisiana and New Jersey), we restricted the
analyses to the SEER 13 regions. Additionally performed
analyses of these four regions provided almost identical
survival estimates for 2005–08 (differences of overall,
age- and stage-specific estimates ranging between 0.2
and 1.7% units; data not shown).
The validity of cancer diagnoses may be considered
high, as almost all tumours were microscopically con-
firmed. When interpreting stage-specific survival, stage
migration (a shift of classification towards more advanced
stages due to increased sensitivity and improved accuracy
of diagnostic procedures) has to be kept in mind [67]. In-
terim revisions of the BRC classification schemes [17-19]
might be of little effect only with regard to the used
clinical stages.
In addition to comparability issues of included patients
and tumour stages, the completeness of follow-up and
estimation of background mortality is crucial in survival
comparisons.
The proportions of DCO notified cases were rather
small in the used databases. Under such circumstances,
the effects of the exclusion of DCO cases from the ana-
lysis or a possible correction for DCO cases are expected
to be very small according to recent work [68].
RS as a measure for survival in the hypothetical situ-
ation where the disease under study would be the only
cause of death (denoted as net survival) is dependent on
the general population mortality (the composition of
cancer patients under follow-up changes over time with
regard to demographic characteristics) [69]. To account
for such dependencies and minimize effects we provided
and used age standardized estimates for inter country
comparison.
The strategy of using the period analysis approach for
all subsequent calendar periods aimed at deriving most
up-to-date estimates (even in case of ongoing improve-
ment) and consistent use of methodology to prevent po-
tential artefacts in the derived time trends due to a
mixture of classical cohort based and period survival
estimates.
The observed trends of RS and corresponding p-values
were considered on their own and carefully interpreted in
the light of further empirical observations. Therefore, we
did not account for multiple testing despite the overall
number of performed statistical tests for significance [70].
Follow-up was almost complete for both the German
and the US patients. It has been shown, that national life
tables may not adequately describe overall mortality of a
subpopulation and result in biased estimates of RS (e.g.
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survival estimates) [71]. Therefore, region- and race-
specific life tables were derived for the analyses.
As the aim of population-based survival analyses is to
provide a picture of the overall control of cancer in the
societies compared, we did not restrict the analyses to
any ethnic subpopulation (e.g. inclusion of white US
patients only). Otherwise this would result in an in-
appropriate selective exclusion of socio-economically
less privileged patients in one of the countries compared.
Additional analyses were performed with a restriction to
white US patients only. The effects of such an exclusion
were generally small (estimates of crude, age standar-
dized and stage adjusted survival estimates of whites
were 1.5% units above estimates of all races combined),
but considerable effects were observed for younger
patients and more advanced stages (e.g. survival of
whites aged 15–49 years with metastasized BRC was
4.5% units higher than estimates of all races combined;
data not shown).
Conclusions
The findings may have several important implications.
Transatlantic differences in 5-year RS and tumour
related excess mortality of BRC patients revealed in pre-
vious studies have continuously decreased in recent
years.
The observed survival trends point to advances in BRC
treatment as a major cause for the gain in prognosis in
both countries. Differences in early detection activities
and effects due to lead time and overdiagnosis further
account for the observed differences.
Whereas most overall improvement was observed for
patients with locally or regionally advanced disease,
prognosis of patients with distant sites involved at diag-
nosis is still limited. Despite interim advances in the
availability of (increasingly costly) treatment options for
patients with metastasized disease, only some moderate
overall improvement has been observed for these
patients during the past 15 years. The implementation of
mammography screening in Germany in recent years
will hopefully further reduce the numbers of breast
tumours with advanced stage.
Particularly for Germany, this study indicated striking
deficits in cancer survival of elderly patients. The gap in
cancer related mortality between elderly patients and
younger ones in Germany has even increased over time.
Inequalities in the access to and provision of cancer care
of elderly patients need to be jointly focussed on in
future by cancer research, health care policy, and the
medical community.
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